| N = 80 | ||
| Median age ABC | 56 years (25 - 75) | |
| Menopausal status | Pre/peri | Post |
|
| 50.0% | 50.0% |
| ABC at diagnosis | yes | no |
|
| 31.3% | 68.7% |
| Metastatic sites | <3 | ≥3 |
|
| 33.8% | 66.2% |
| Ovarian suppression with goserelin | yes | no |
|
| 28.7% | 71.3% |
| Prior Chemotherapy | yes | no |
|
| 27.5% | 72.5% |
| Hormonal resistance | yes | no |
|
| 55.0% | 45.0% |
| Ci | 1st line | >1st line |
|
| 68.8% | 31.2% |
| 1˚ Ci | Palbociclib | Ribociclib |
|
| 73.8% | 26.2% |
| Hormonal partner | Non Steroidal aromatase inhibitor | Fulvestrant |
|
| 45.0% | 55.0% |
| Non Steroidal aromatase inhibitor | Anastrozol | Letrozol |
|
| 44.4% | 55.5% |
| Ci toxicity | Deferrals | Dose reduction |
| 71.3% | 31.3% | |
| Concomitant PPi | yes | no |
|
| 37.5% | 62.5% |
| Concomitant PPi time | all | parcial |
|
| 70.0% | 30.0% |
| Which PPi | Omeprazol | Pantoprazol |
|
| 23.3% | 73.4% |
| Progression of disease under Ci | yes | no |
|
| 57.5% | 42.5% |